Share on StockTwits

Regeneron Pharmaceuticals (NASDAQ:REGN) hit a new 52-week high on Tuesday after Credit Suisse raised their price target on the stock from $340.00 to $400.00, Analyst RN reports. Credit Suisse currently has an outperform rating on the stock. Regeneron Pharmaceuticals traded as high as $369.31 and last traded at $363.61, with a volume of 952,355 shares. The stock had previously closed at $350.45.

A number of other analysts have also recently weighed in on REGN. Analysts at Leerink Swann raised their price target on shares of Regeneron Pharmaceuticals from $389.00 to $436.00 in a research note on Tuesday. They now have an “outperform” rating on the stock. Separately, analysts at Zacks downgraded shares of Regeneron Pharmaceuticals from an “outperform” rating to an “underperform” rating in a research note on Tuesday, August 26th. They now have a $316.00 price target on the stock. Finally, analysts at RBC Capital raised their price target on shares of Regeneron Pharmaceuticals from $349.00 to $373.00 in a research note on Wednesday, August 6th. They now have an “outperform” rating on the stock. One research analyst has rated the stock with a sell rating, six have given a hold rating and fourteen have assigned a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus price target of $352.11.

In other Regeneron Pharmaceuticals news, Director Joseph L. Goldstein sold 2,000 shares of the company’s stock on the open market in a transaction dated Wednesday, August 27th. The stock was sold at an average price of $350.31, for a total transaction of $700,620.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

The stock has a 50-day moving average of $328.2 and a 200-day moving average of $312.7. The company has a market cap of $36.620 billion and a P/E ratio of 99.73.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings results on Tuesday, August 5th. The company reported $2.47 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.30 by $0.17. The company had revenue of $666.00 million for the quarter, compared to the consensus estimate of $647.99 million. During the same quarter in the previous year, the company posted $1.73 earnings per share. The company’s revenue for the quarter was up 45.4% on a year-over-year basis. Analysts expect that Regeneron Pharmaceuticals will post $10.15 EPS for the current fiscal year.

Regeneron Pharmaceuticals, Inc (NASDAQ:REGN) is an integrated biopharmaceutical company, which discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions.

Receive News & Ratings for Regeneron Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.